# Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines

> **NCT05142540** · — · TERMINATED · sponsor: **Medical University of Graz** · enrollment: 140 (actual)

## Conditions studied

- Anti-SARS-CoV-2 Antibody Response

## Interventions

- **PROCEDURE:** blood and saliva samples will be taken

## Key facts

- **NCT ID:** NCT05142540
- **Lead sponsor:** Medical University of Graz
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-10-04
- **Final completion:** 2022-10-04
- **Target enrollment:** 140 (ACTUAL)
- **Why stopped:** No more booster vaccinations are being carried out at the site. Further recruitment is therefore not possible.
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142540, "Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05142540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*